Kencur for Pain and Inflammation: The EPMC Pharmacology

This is kencur's deepest evidence base by a wide margin, and it is almost entirely the story of one molecule: ethyl p-methoxycinnamate (EPMC), which can make up more than half of the rhizome's essential oil by weight. Across two decades of research and an unusually active burst of new chemistry since 2023, EPMC and its close relatives have been shown to inhibit inflammatory mediators at several distinct points in the pathway, relax isolated blood vessels through an entirely separate mechanism, and, in one 2026 study, outperform diclofenac in a mouse model of induced inflammation. None of it has been tested in a person. This page works through what is actually known, compound by compound and study by study.

Table of Contents

  1. Why EPMC Is the Story
  2. The Leukotriene, Prostaglandin, and NF-κB Evidence
  3. New Phenylpropanoid Chemistry From the Last Two Years
  4. EPMC Against a Named Viral Target: Dengue
  5. A 2026 Animal Model of Sinus Inflammation
  6. A Different Tissue Entirely: Vasorelaxation
  7. What a Rodent Pain-Model Positive Does and Does Not Tell You
  8. The Safety Signal: hERG, Liver, and Neurons
  9. What This Evidence Does Not Show
  10. Practical Takeaway
  11. Key Research Papers
  12. Connections

Why EPMC Is the Story

Most herbs on this site have a diffuse chemistry — dozens of compounds, no single one dominant, and a correspondingly diffuse evidence base where a claimed benefit might trace to any of several constituents. Kencur is unusual in the opposite direction. Ethyl p-methoxycinnamate is not merely a major constituent of the rhizome; depending on origin, harvest timing, and distillation method, it can be a quarter to more than half of the essential oil by weight, and it is the compound researchers isolate first and test most, precisely because it is easy to obtain in quantity and because it is what makes kencur smell the way it does.

That concentration works in this page's favor for one purpose and against it for another. In its favor: when a study reports "Kaempferia galanga extract" produced an effect, there is a real chance the effect traces specifically to EPMC rather than to some minor, unidentified trace compound — several of the studies below isolated EPMC directly and tested it alone, which is the strongest form of evidence a plant-chemistry paper can offer short of a clinical trial. Against it: a molecule this potent and this concentrated is also not free of biological activity elsewhere in the body, which is why the safety section below matters as much as the pharmacology.

Back to Table of Contents

The Leukotriene, Prostaglandin, and NF-κB Evidence

The clearest mechanistic thread running through kencur's anti-inflammatory research is interference with the arachidonic acid cascade — the enzymatic assembly line that converts membrane fatty acids into the prostaglandins and leukotrienes responsible for pain, swelling, fever, and immune cell recruitment.

Dwita and colleagues (2021) tested extracts, fractions, and isolated EPMC from Kaempferia galanga and reported that all three limited production of leukotriene B4 (LTB4), a potent chemical signal that recruits neutrophils into inflamed tissue. LTB4 is a specific, named target, not a vague "anti-inflammatory" claim, and the fact that isolated EPMC reproduced the whole-extract effect strengthens the attribution.

Sukkasem and colleagues (2024) took a different and more rigorous approach: rather than studying kencur alone, they analyzed Kheaw-Hom, a Thai traditional remedy on that country's National List of Essential Medicines, used clinically for fever and inflammation in children. Crucially, they first confirmed by HPLC that EPMC was actually present in the remedy — 21.33 mg per gram of extract in the most concentrated preparation — before crediting any effect to it, which is exactly the check that formula-based herbal evidence needs and often does not get. With that established, EPMC inhibited prostaglandin E2 (PGE2), nitric oxide, and TNF-alpha production in macrophage cell culture, and the whole remedy reduced paw and ear edema in rats through the same pathway.

The self-microemulsion gastric-ulcer study covered on the digestive health page found the same NF-κB/COX-2 suppression operating in stomach tissue, which is a useful cross-check: the same molecular pathway showing up in two unrelated tissue types (paw, stomach) by two unrelated research groups is a more convincing signal than either finding alone.

Back to Table of Contents

New Phenylpropanoid Chemistry From the Last Two Years

Kencur's active-compound catalog is still expanding, and quickly. Three papers from 2025 and 2026 describe entirely new molecules isolated from the rhizome, all built around the same phenylpropanoid chemistry that produces EPMC:

Two things are worth saying honestly about this cluster. First, "new compound, active in a nitric-oxide-inhibition assay" is a common and relatively easy result to obtain in a natural-products chemistry lab; it establishes that a molecule can modulate one inflammatory readout in a dish, not that it has any therapeutic effect in a whole organism, let alone a person. Second, and more usefully, the consistency across independent Chinese, Japanese, and Indonesian research groups isolating structurally related molecules with a shared mechanism is a real signal that kencur's phenylpropanoid chemistry as a class does something to this pathway — it is simply a signal about chemistry and cell biology, several steps removed from a clinical claim.

Back to Table of Contents

EPMC Against a Named Viral Target: Dengue

One 2024 finding stands out from the rest for testing a specific, real-world clinical problem rather than a generic inflammation readout. Tarasuk and colleagues identified Kaempferia galanga extract as having activity against dengue virus, and traced the effect to EPMC specifically. In two human cell lines (HepG2 liver cells and A549 lung cells — laboratory cell culture, not a person), EPMC reduced dengue virus-2 infection, virus particle production, and viral protein synthesis, with a favorable selectivity index (meaning it affected the virus at concentrations well below what harmed the host cells) of up to 173 in the A549 line. It was active against all four dengue serotypes.

The inflammatory side of the same study is what makes it a dual finding rather than a purely antiviral one: dengue's dangerous complications come largely from a virus-triggered cytokine storm, and EPMC reduced dengue-induced IL-6, TNF-alpha, and two chemokines (RANTES and IP-10) by suppressing NF-κB activation — the same transcription factor implicated in the leukotriene and prostaglandin work above. The researchers also ran computational toxicity and drug-likeness predictions (SwissADME, ProTox II) and found no red flags, though this is a predictive screen, not a safety study.

This is genuinely interesting cell-culture pharmacology and a plausible reason for future animal-model dengue research. It is not evidence that eating kencur, drinking beras kencur, or taking a kencur supplement affects a dengue infection in a person, and nothing about this study should be read as a treatment recommendation for a serious mosquito-borne illness that requires medical management.

Back to Table of Contents

A 2026 Animal Model of Sinus Inflammation

The newest and most clinically-framed study in this collection, published in early 2026, tested Kaempferia galanga extract in a rat model of acute bacterial rhinosinusitis — induced sinus infection, the same condition behind a bad sinus infection in a person. Eighteen rats with induced disease were split across three dose groups (150, 300, and 450 mg/kg) and assessed by three blood markers: malondialdehyde (MDA, an oxidative-stress marker), NF-κB, and CRP (C-reactive protein, a standard clinical inflammation marker).

The middle dose, 300 mg/kg, produced the lowest levels of all three markers — better than both the lower and the higher dose. That non-monotonic result (more is not simply better) is worth flagging rather than glossing over: it could reflect a genuine biphasic dose-response, a real and recognized phenomenon in pharmacology, or it could reflect the limits of an 18-animal, three-arm study, where six rats per group leaves relatively little room to distinguish a true optimum from noise. Either way, it is a reason for caution about any specific dose number, not a reason to dismiss the finding that the extract did something at all doses relative to the untreated comparison implied by the design.

This is one rat study, unreplicated, for a condition — sinusitis — that does not otherwise appear in kencur's traditional-use record on the main Kencur page (traditional use centers on cough, digestive complaints, and topical aches, not specifically sinus infection). It is included here because it is real, recent, and methodologically clear about its doses and its markers — not because it supports a specific recommendation for sinusitis.

Back to Table of Contents

A Different Tissue Entirely: Vasorelaxation

Separate from every inflammation finding above, Srivastava and colleagues (2021) found that EPMC relaxes isolated rat mesenteric arteries — a blood-vessel effect, not a pain or inflammation effect, and worth distinguishing clearly rather than folding into the same story. Using arteries pre-contracted with a thromboxane mimetic, EPMC produced dose-dependent relaxation of roughly 59–62%. The mechanism, worked out with channel blockers, runs through calcium-activated potassium (BKca) channels in the smooth muscle, independent of the vessel's endothelial lining.

Why this belongs on the inflammation page rather than being its own claim: it is genuine, specific pharmacology, but it is a different tissue (vascular smooth muscle, not neural or immune tissue) and a different endpoint (vessel diameter, not pain or swelling) from everything else in this article. It should not be read as evidence for a blood-pressure-lowering health claim — no blood-pressure study, in an animal or a person, has been run — and it should especially not be conflated with the sedative, CNS-depressant pharmacology covered on the sedative pharmacology page, which is a genuinely separate mechanism in a genuinely separate organ system, even though both trace back to the same molecule. One EPMC, two unconnected physiological effects, in two different tissues — that is a fact about a versatile molecule, not evidence that either effect is stronger or more clinically relevant than it is.

Back to Table of Contents

What a Rodent Pain-Model Positive Does and Does Not Tell You

The main Kencur page already states plainly that rodent pain models are notorious for producing positives that fail to translate to humans, and that remains the single most important caveat on this entire page. It is worth explaining briefly why, rather than treating it as a boilerplate disclaimer.

Rodent inflammation and nociception models — carrageenan paw edema, formalin-induced pain, acetic acid writhing — measure a proxy (paw swelling, withdrawal reflex, writhing behavior) for a human experience (pain, as reported by the person having it) that cannot be measured directly in an animal. The biochemical pathway being tested (prostaglandins, leukotrienes, NF-κB) is real and shared between rodents and humans, which is why these models are used at all and why a positive result is scientifically meaningful as a first step. But the translation rate from "reduced rodent paw edema" to "effective, clinically meaningful pain relief in a randomized human trial" is poor across pharmacology generally — a large fraction of compounds that look promising in these exact assays fail in human trials, for reasons ranging from dose and bioavailability differences to the models simply not capturing what matters about human pain.

Sarmoko and colleagues' 2026 finding that EPMC resolved carrageenan-induced paw edema in mice faster than diclofenac sodium (a standard NSAID comparator) is a striking result, but it comes from a very small study — three mice per group — which is far below what a modern pharmacology journal would expect for a claim intended to generalize, and it is exactly the kind of promising rodent result the paragraph above is warning about. It is reported here because it is real and because comparing a natural compound favorably to a licensed drug in an animal model is scientifically interesting; it is not reported as evidence that kencur outperforms diclofenac for a person's pain.

Back to Table of Contents

The Safety Signal: hERG, Liver, and Neurons

A 2025 safety screen by Kasemnitichok and colleagues tested EPMC alongside five other compounds common in Thai traditional medicine (including curcumin and alpha-mangostin) against three separate toxicity endpoints: HepG2 liver-cell viability, neurotoxicity in ReNcell VM neural progenitor cells, and inhibition of the hERG cardiac potassium channel — the standard early-warning test for drug-induced heart rhythm problems, using an automated patch-clamp technique in HEK293 cells engineered to express the channel.

The result for EPMC specifically was reassuring relative to the other compounds tested: it showed no significant liver or neural cytotoxicity at the concentrations tested, and low hERG inhibition (IC50 = 53 µM, the weakest hERG effect of the four low-inhibition compounds in the panel). The authors' own conclusion was that, at regular clinical or dietary concentrations, EPMC and the other tested compounds are unlikely to cause significant side effects through these three specific mechanisms — while explicitly noting that if any of these compounds were developed into an actual drug, hERG effects would need formal preclinical and clinical pharmacokinetic study.

This pairs with an older toxicology study: Kanjanapothi and colleagues (2004) ran acute and 28-day subacute toxicity testing of the ethanolic rhizome extract in rats. A single 5 g/kg oral dose produced no mortality and no detectable organ or histopathological change. Repeated daily dosing at 25, 50, or 100 mg/kg for 28 days likewise produced no mortality, no organ-weight changes, and normal blood chemistry (glucose, kidney and liver enzymes), with one specific, minor exception: a small but statistically significant drop in lymphocyte count in male rats at the 50 and 100 mg/kg doses. The same study's initial screening test also documented clear signs of CNS depression — reduced motor activity, reduced respiratory rate, loss of grip reflex, and analgesia — which is the animal pharmacology behind the sedative effects covered in detail on the sedative pharmacology page.

Taken together, these two safety studies, twenty years apart, are consistent with each other and with kencur's long history as a food: no acute lethality, no major organ toxicity at the doses tested, a minor and isolated blood-count change worth monitoring in any future study, and a real, reproducible CNS-depressant signal. None of this is human safety data, and none of it substitutes for a formal toxicology or pharmacokinetic study, which has not been done.

Back to Table of Contents

What This Evidence Does Not Show

Stated plainly, because it is easy to lose track of across a page this dense with mechanism: not one of the studies above was conducted in a human subject. A systematic search of PubMed's title and abstract fields, phrase-locked to Kaempferia galanga to exclude the frequently confused Kaempferia parviflora (black ginger), for any combination of "randomized," "clinical trial," "human," "patients," "volunteers," or "subjects," returns 25 papers — and reading every one shows that all 25 involve either a human cell line in a dish (HepG2 liver cells, human gingival fibroblasts, human dermal fibroblasts, human lymphocytes), a pathogen described as infecting humans (Helicobacter pylori as "the human carcinogen"), or a study explicitly hoping its animal results might one day "be extrapolated to an animal or human system." None is a trial conducted on a person.

This matters for the specific reason that, on other herb pages built alongside this one, an identically-worded claim on the existing hub page ("no human data," "essentially none") turned out to have been overtaken by new research published after the original page was written. That is not the case here. The main Kencur page's statement is accurate as of this review, not stale, and the anti-inflammatory story told across this page — however mechanistically rich — remains a laboratory and animal story from beginning to end.

Back to Table of Contents

Practical Takeaway

Kencur used as a kitchen spice, in the amounts a Javanese or Malay kitchen actually uses (a few grams in a dish serving several people), sits within a long, apparently safe culinary tradition and is a reasonable, low-risk way to enjoy a genuinely interesting flavor. Nothing in the pharmacology above changes that assessment either direction. What it does not support is treating a kencur capsule, extract, or essential oil as a substitute for evaluated anti-inflammatory or pain treatment for a real medical condition — arthritis, an infection, an injury, or anything requiring diagnosis. If a kencur-based topical rub or tea feels good on a sore muscle, that is a reasonable thing to enjoy for the sensation itself; it is not treatment, and persistent pain deserves an actual diagnosis.

Back to Table of Contents

Key Research Papers

  1. Dwita LP, Hikmawanti NPE, Yeni, et al. Extract, fractions, and ethyl-p-methoxycinnamate isolate from Kaempferia galanga elicit anti-inflammatory activity by limiting leukotriene B4 (LTB4) production. Journal of Traditional and Complementary Medicine, 2021;11(6):563–569. — PubMed
  2. Sulaiman MR, Zakaria ZA, Daud IA, et al. Antinociceptive and anti-inflammatory activities of the aqueous extract of Kaempferia galanga leaves in animal models. Journal of Natural Medicines, 2008;62(2):221–227. — PubMed
  3. Sukkasem K, Itharat A, Thisayakorn K, et al. Exploring in vitro and in vivo anti-inflammatory activities of the Thai traditional remedy Kheaw-Hom and its bioactive compound, ethyl p-methoxycinnamate. Journal of Ethnopharmacology, 2024;319(Pt 1):117131. — PubMed
  4. Sarmoko, Suprahman NY, Saputro AH, et al. Ethyl p-methoxycinnamate exhibits superior multi-modal anti-inflammatory activity compared to structurally related cinnamic acid derivatives. Journal of Pharmacopuncture, 2026;29(1):61–74. — PubMed
  5. Tarasuk M, Songprakhon P, Muhamad P, et al. Dual action effects of ethyl-p-methoxycinnamate against dengue virus infection and inflammation via NF-κB pathway suppression. Scientific Reports, 2024;14(1):9322. — PubMed
  6. Putri AVB, Dirgahayu P, Purwanto B, et al. Anti-inflammatory and antioxidant effects of Kaempferia galanga extract in acute bacterial rhinosinusitis: in vivo study on MDA, NF-κB, and CRP. Iranian Journal of Otorhinolaryngology, 2026;38(1):37–42. — PubMed
  7. Tao SF, Gongpan P, Chen RK, et al. Six unusual monoterpene-phenylpropanoid [2+3] cycloadducts from Kaempferia galanga with anti-inflammatory activity. Fitoterapia, 2026;190:107161. — PubMed
  8. Mufidah S, Miyamae Y, Fuchino H, Kawahara N. Kaemphenolide: a cyclobutane-bearing phenylpropanoid from Kaempferia galanga L. with nitric oxide inhibitory activity. Natural Products and Bioprospecting, 2025;15(1):68. — PubMed
  9. Srivastava N, Mishra S, Iqbal H, Chanda D, Shanker K. Standardization of Kaempferia galanga L. rhizome and vasorelaxation effect of its key metabolite ethyl p-methoxycinnamate. Journal of Ethnopharmacology, 2021;271:113911. — PubMed
  10. Kasemnitichok Y, Lee S, Kwon OB, Plengsuriyakarn T, Na-Bangchang K. Insights into hepatic, neuronal, and hERG channel safety of plant-derived active compounds. Journal of Xenobiotics, 2025;15(6):175. — PubMed
  11. Kanjanapothi D, Panthong A, Lertprasertsuke N, et al. Toxicity of crude rhizome extract of Kaempferia galanga L. (Proh Hom). Journal of Ethnopharmacology, 2004;90(2–3):359–365. — PubMed
  12. Ko HJ, Kim HJ, Kim SY, et al. Hypopigmentary effects of ethyl p-methoxycinnamate isolated from Kaempferia galanga. Phytotherapy Research, 2014;28(2):274–279. — PubMed
  13. Antiangiogenic effects and mechanisms of trans-ethyl p-methoxycinnamate from Kaempferia galanga L. Journal (2012). — PubMed

Back to Table of Contents

Connections

Back to Table of Contents